Compare SQNS & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | NSPR |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 77.5M |
| IPO Year | 2011 | 2009 |
| Metric | SQNS | NSPR |
|---|---|---|
| Price | $3.09 | $1.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $20.33 | $4.00 |
| AVG Volume (30 Days) | ★ 118.4K | 23.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $22.91 |
| Revenue Next Year | $62.85 | $72.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $1.51 |
| 52 Week High | $10.93 | $3.34 |
| Indicator | SQNS | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 39.32 |
| Support Level | $2.72 | $1.56 |
| Resistance Level | $5.85 | $2.51 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 83.64 | 8.97 |
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.